What Researchers Did
Researchers conducted a narrative review of 68 clinical studies to assess the rationale and evidence for hyperbaric oxygen therapy (HBOT) in acute acoustic trauma (AAT) and idiopathic sudden sensorineural hearing loss (ISSHL).
What They Found
The review found that hyperbaric oxygen therapy (HBOT) has been extensively used for acute hearing loss over the past decades, with 68 studies showing a positive effect. Based on these findings, HBOT should be considered an optional therapy for patients with acute acoustic trauma or idiopathic sudden sensorineural hearing loss, ideally initiated within 48 hours and combined with corticosteroids.
What This Means for Canadian Patients
Canadian patients experiencing acute hearing loss, such as acute acoustic trauma or idiopathic sudden sensorineural hearing loss, may consider discussing hyperbaric oxygen therapy (HBOT) as a potential treatment option with their healthcare providers. For optimal outcomes, this therapy, potentially combined with corticosteroids, should ideally be initiated as early as possible, preferably within 48 hours of onset.
Canadian Relevance
This narrative review does not have a direct Canadian connection.
Study Limitations
As a narrative review, this study may be subject to selection bias and lacks the systematic rigor of a meta-analysis, potentially limiting the generalizability of its conclusions.